Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition

被引:44
作者
Miller, Dave A. [1 ]
DiNunzio, James C. [1 ]
Yang, Wei [1 ]
McGinity, James W. [1 ]
Williams, Robert O., III [1 ]
机构
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
关键词
itraconazole; supersaturation; in vivo; bioavailability; enteric; solid dispersion; solid solution; hot melt extrusion; amorphous;
D O I
10.1080/03639040801929273
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previous attempts to improve the dissolution and absorption properties of itraconazole (ITZ) through advanced formulation design have focused only on release in acidic media; however, recent reports indicate that absorption occurs primarily in the proximal small intestine. This suggests that enhancing supersaturation of ITZ in neutral aqueous environments is essential for improving absorption. The aim of this study was to evaluate different polymeric stabilizers with either immediate release (IR) (Methocel (TM) E5, Methocel (TM) E50, Kollidon (R) 12, and Kollidon (R) 90) or enteric release (EUDRAGIT (R) L 100-55, HP-55, and HP-55S) properties to determine the chemical and physical attributes of the polymeric stabilizers that promote supersaturation of ITZ in neutral media. Each amorphous composition was produced by hot-melt extrusion and characterized by differential scanning calorimetry. Dissolution testing by a supersaturated acidic-to-neutral pH change method was conducted on each composition. Testing of IR compositions revealed that Methocel (TM) was a superior stabilizer compared with Kollidon (R) owing to stronger intermolecular interaction with ITZ molecules in solution. Increasing the molecular weight of polymers was found to promote ITZ supersaturation and was most likely attributable to increased solution viscosity resulting in retention of ITZ molecules in an enthalpically favored association with the polymer for extended durations. Of the enteric polymeric stabilizers, EUDRAGIT (R) L 100-55 was found to be superior to both HP-55 grades because of its greater permeability to acid that allowed for improved hydration of ITZ in the acid phase as well as a greater number of free hydroxyl groups on the polymer backbone that presumably helped to stabilize ITZ in solution. The Methocel (TM) E50 and EUDRAGIT (R) L 100-55 formulations were evaluated for in vivo drug absorption in male Sprague-Dawley rats and were found to produce a threefold greater ITZ absorption over our previously reported IR formulations. The results of this study confirmed the hypothesis that supersaturation of ITZ following an acidic-to-neutral pH transition in vitro correlates directly to in vivo absorption.
引用
收藏
页码:890 / 902
页数:13
相关论文
共 45 条
[1]   Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies [J].
Bohme, A ;
JustNubling, G ;
Bergmann, L ;
Shah, PM ;
Stille, W ;
Hoelzer, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (06) :953-961
[2]   NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS [J].
DENNING, DW ;
LEE, JY ;
HOSTETLER, JS ;
PAPPAS, P ;
KAUFFMAN, CA ;
DEWSNUP, DH ;
GALGIANI, JN ;
GRAYBILL, JR ;
SUGAR, AM ;
CATANZARO, A ;
GALLIS, H ;
PERFECT, JR ;
DOCKERY, B ;
DISMUKES, WE ;
STEVENS, DA .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) :135-144
[3]   Invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :781-803
[4]   Epidemiology of nosocomial fungal infections [J].
Fridkin, SK ;
Jarvis, WR .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :499-&
[5]   Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations [J].
Gao, P ;
Guyton, ME ;
Huang, TH ;
Bauer, JM ;
Stefanski, KJ ;
Lu, Q .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (02) :221-229
[6]   Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies:: Evidence from a meta-analysis of 3,597 patients [J].
Glasmacher, A ;
Prentice, A ;
Gorschlüter, M ;
Engelhart, S ;
Hahn, C ;
Djulbegovic, B ;
Schmidt-Wolf, IGH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4615-4626
[7]   ITRACONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1989, 37 (03) :310-344
[8]   Trends in the postmortem epidemiology of invasive fungal infections at a university hospital [J].
Groll, AH ;
Shah, PM ;
Mentzel, C ;
Schneider, M ;
JustNuebling, G ;
Huebner, K .
JOURNAL OF INFECTION, 1996, 33 (01) :23-32
[9]   Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum [J].
Gubbins, PO ;
Gurley, BJ ;
Bowman, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 16 (06) :1005-1012
[10]   PHARMACOKINETICS OF ITRACONAZOLE FOLLOWING ORAL-ADMINISTRATION TO NORMAL VOLUNTEERS [J].
HARDIN, TC ;
GRAYBILL, JR ;
FETCHICK, R ;
WOESTENBORGHS, R ;
RINALDI, MG ;
KUHN, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1310-1313